anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a composition useful in as a hair growth promoter which contains an extract drawn from a plant having a pseudo bulb selected from the group consisting of Calanthe R. Br. and Phaius Lour. The extract can be obtained from either a portion of a plant or the pseudo bulb of Calanthe discolor Lindl. or Phaius flavus (Blume) Lindl. by extraction of such a plant in an extraction solvent. The composition may include vitamins, amino acids, animal and plant oils, and sodium chloride. When applied to an area of skin afflicted with alopecia, the composition is useful for promoting hair growth.
FIELD: veterinary. SUBSTANCE: essence of this method resides in administering anti-brucillosis vaccine prepared from Brucella strain No. 82 and after expiry of 40 to 48 days administering dose of 2.5 to 3.0 ml of anticampilobacterial vaccine derived from strain No. 1123. EFFECT: disclosed method permits one-hundred-percent immunity against brucelloses and campilobacteriosis. 1 tbl
FIELD: chemistry. ^ SUBSTANCE: in formulas (I) and (Ia) . A is 1-cyclopentene-1,2-diyl; Z1 and Z2 are O; E is phenyl substituted with 1-4 substituting groups selected from halogen, Y is phenyl substituted with 1-2 substituting groups selected from halogen, C1-C6alcoxy, halogen C1-C6alcoxy; the meaning of other radicals are indicated in the formula of the invention. The invention refers also to the pharmaceutical composition including the compound of the invention, to the application of the said compound at preparation of the medicinal agent and to the application for DHODH inhibition. ^ EFFECT: compound of the present invention can find application as medicinal agent inhibiting dehydroorotate dehydrogenase. ^ 9 cl, 18 ex
This is a randomized (study medication assigned by chance), placebo controlled, double-blind (neither physician or subject knows the name of the assigned study medication) study to assess the safety, tolerability, immune response, pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of CNTO 5825. The study population will consist of 48 healthy volunteers and 16 healthy atopic volunteers. Five dose levels of study agent will be assessed. Participants will be required to stay at the research center after study agent administration for the inpatient portion of the study and then return for out-patient visits. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. Placebo (containing inactive substances only) or one of five dose levels of CNTO 5825 will be given. Healthy volunteers will be given a single IV infusion (directly into a vein) or a single dose of up to 3 injections under the skin. Healthy atopic volunteers will be given one dose as as an IV infusion. There will be a screening period of up to 4 weeks. All participants will be in the study for 17 weeks after dose administration.
A total of thirty (30) subjects will be enrolled and assigned to a single treatment arm, receiving active treatment clinic, with the visits consisting of three (3) treatment administrations and post-procedure visits days 30, 180 and 360. Pre-menopausal and post-menopausal women between ages over 18, vaginal delivery, with up to moderate pelvic prolapse 2 cm past the hymen, and self-reported vaginal laxity score of "very loose", moderately loose", or "slightly loose" as defined by theVaginal Laxity Questionnaire (VLQ) will be evaluated and enrolled after having met all inclusion and exclusion criteria.

The treatment administration phase will consist of three (3) treatments,delivered approximately on-month apart. Subjects will be placed on the treatment table in the dorsal lithotomy position. The monopolar return pad will be placed on the subject buttock and to the RF generator.Coupling fluid will be used as a lubricant and will be reapplied throughout the treatment as needed. The treatment area is approximately 20+ cm2 and consist of the outside perineum and entire vaginal circumference along the length of the vagina to include the apex. For treatment of the labia majora, the treatment tip will be applied across the entire anatomical region. The treatment tip is applied to the perineum bilaterally from the lowest edge of the mons pubis to the perineal body and laterally to the crural folds to achieve vulvar and perineal temperatures of between 40-45 degrees celsius for approximately 5 minutes or more of total heat time per area. The labia majora and perineal areas will take approximately 10-15 minutes to complete. This is followed by treating the epithelial surface of the vaginal opening and advancing to the length of the vaginal canal with the treatment occurring along the vaginal walls, floor, and ceiling. The entire vaginal area will be treated in a circumferential area by delivering the RF in a systematic fashion at 5 separate delivery position starting the most distal portion of the vagina. The probe is slowly retracted at 1 cm intervals and circumferentially delivered again at 5 positions on another circumferentially manner moving the probe clockwise or counter clockwise or counter clockwise. To include the entire length of the urethra and bladder will be included in the treatment. Total vaginal treatment time will be 15-20 minutes. Safety measures will include monitoring of adverse events including pain or burns or infections during and after the procedure. Evaluations will be conducted with the visits at days 30, 90 and 150 days post-procedure.

During and after treatment administration, subjects will be asked to assess the self- reported pain experience using a 10 scale VAS, with "0" being no pain and "10" being the worst pain imaginable. Descriptive statistics will be generated on all demographic, medical history, and physical examination findings including means and standard deviations, for continuous, and frequencies and percentages for categorical variables.
The long-range goal of the proposed research is to formulate design survival statistics that will aid the dental community in fabricating properly designed prostheses that can predictably survive the oral environment.

Patients who qualify for this study will be randomized (as in chanced with the flip of a coin) into two groups. The first group is a metal-ceramic group where patients will receive a bridge with a metal substructure underneath. The second group is an all-ceramic group where patients will receive a bridge which is made of hard ceramic material. All patients will receive two dental implants which will bond to bone for a period of 4-6 months. An impression or mold of the implants will then be made and a bridge will be fabricated based on the randomization of the patient. Patients will be asked to return at 6 months and yearly thereafter up to 5 years. During these recall appointments, photographs will be taken and impressions of the bridge and other teeth will be made. This will allow us to measure the amount of wear happening with the bridge and the other teeth. The investigators can also examine the amount of bone around the implants as well as the integrity of the bridge.
The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
This study presents a comprehensive comparative proteomic analysis aimed at elucidating the molecular mechanisms underlying male androgenetic alopecia (AGA) and female AGA. Scalp samples from both male AGA and female AGA patients, along with their respective normal controls, were subjected to proteomic analysis, followed by bioinformatics investigations. Our findings revealed distinct proteomic profiles between male AGA and female AGA, with a total of 68 differentially expressed proteins identified in male AGA and 84 in female AGA. Among these, specific proteins were altered in male AGA and female AGA, highlighting the sex-specific molecular pathways involved in the pathogenesis of pattern hair loss. Protein-protein interaction network analyses further delineated the most impacted biological processes, including cytoskeleton organization, stress response, and metabolic pathways, with particular emphasis on the differing altered stress responses and metabolic states associated with hair loss between sexes. Our study not only uncovered the complex molecular landscape of male AGA and female AGA but also identified potential biomarkers and therapeutic targets, offering new insights into the sex-specific pathogenesis of pattern hair loss.
BACKGROUND: Laparoscopic appendicectomy is commonly performed in Australia for treatment of acute appendicitis. Intra-abdominal abscess (IAA) is a potential complication following appendicectomy for acute appendicitis. Risk factors for developing post-operative IAA remain controversial and poorly defined. Laparoscopic washout may be performed for patients who develop complication(s) including IAA. The aim of this study was to define risk factors for both the development of IAA and identify patients who may require laparoscopic washout following appendicectomy.
METHODS: Data were obtained from 423 patients who underwent laparoscopic appendicectomy over a five-year period (2012-2017). Clinical (fever, haemodynamics, examination findings), biochemical (white cell count, neutrophil count, C-reactive protein, bilirubin, albumin), radiological (CT free fluid), and operative factors (inflammation, suppuration, free-fluid, perforation, histopathology) collected in the pre-, peri-, and post-operative period(s) were analysed.
RESULTS: 23 (5.4%) patients developed post-operative IAA. Duration of intravenous antibiotics was significantly longer in patients who developed IAA and in those who required laparoscopic washout (p < 0.0001). C-reactive protein (CRP) on admission (p < 0.05) and appendiceal perforation (p = 0.0005) were significantly higher in patients who either developed IAA or needed laparoscopic washout. No clinical or radiological finding predicted either the development of IAA or need for laparoscopic washout.
CONCLUSION: Elevated CRP on admission may predict the development of post-operative IAA formation or the need for laparoscopic washout post-appendicectomy. Prolonged post-operative antibiotic use appears independent of the development of IAA as well as the need for laparoscopic washout. These data highlight the need for clear guidelines on peri-operative antibiotic use following appendicectomy.
The present invention provides a method for maintaining a therapeutically effective concentration of idoxifene for treating a patient with bipolar I disorder. The method comprises administering to the patient a dose of 2mg to 16mg once daily of indoxifene citrate in the form of an enteric coated tablet for at least 21 days. Further, the method provides desirable in vivo plasma properties. No therapeutic dose monitoring is required in patients undergoing such treatment. In addition, the method provides a significant improvement in mania in patients undergoing said treatment, as assessed by the YMRS and MADRS scores. In addition, the method allows patients undergoing said treatment to develop an early response time within at least 2 days of treatment and a remission time of no more than 4 days of treatment.
The invention provides a neutralizing antibody for a novel coronavirus receptor binding region and application thereof, belonging to the technical field of biological products, wherein the neutralizing antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region includes the heavy chain CDR3 shown in SEQ ID NO. 3 or SEQ ID NO. 13, and the light chain variable region includes the light chain CDR3 shown in SEQ ID NO. 6 or SEQ ID NO. 16. The invention obtains the neutralizing antibodies C14646P3S and C2767P3S of the SARS-CoV-2 receptor binding region by LIBRA-seq high-throughput screening, has stronger neutralizing capacity to SARS-CoV-2 pseudovirus and live virus in vitro, can well block the binding of the novel coronavirus receptor binding region and the receptor thereof, and has important application value in the aspects of preventing, treating and diagnosing SARS-CoV-2 infection.
The invention provides a sperm production formula for treating male infertility. The sperm production formula has a function of nourishing kidney yin and is mainly used for treating the male infertility such as mentulagra, spermatorrhea, oligospermia and low sperm motility which are caused by deficiency of the kidney. The sperm production formula is prepared from the following raw material medicines by weight: codonopsis pilosula, rehmannia glutinosa, dioscorea opposita thunb, pulp of dogwood fruit, lycium barbarum and tortoise plastron. The sperm production formula has an excellent effect for treating the infertility due to azoospermatism, oligospermia and normal number of sperms. The composition has the excellent and rapid treatment effect for the male infertility, and has no side effect to a human body because of being prepared by utilizing natural Chinese medicine ingredients. The sperm production formula can be used for strengthening the sperms and effectively increasing the number of the sperms.
The gut acts as a barrier to bacteria and nutrients and participates in glucose homeostasis via endocrine actors and the gut-brain-peripheral axis. It is unclear how T2D alters microbes in upper and lower intestine of humans. Studies in animals show that T2D promotes translocation of microbes to the blood and tissues to promote metabolic dysfunction. It is crucial to determine whether bacteria or their components subvert the gut barrier in human T2D, and then to identity the relevant bacterial strains in tissues that control blood glucose. The overall objective of our research program is to demonstrate that specific microbes in the gut, circulation, and key metabolic tissues are involved in the progression of T2D. We will define the microbial signatures of T2D in duodenal biopsies and stool samples by comparing T2D and non-T2D subjects.
Ligularia fischeriTurcz. is a medicinal plant for the treatment of inflammation in China and Korea. Its chemical components in anti-sepsis activity and the related molecular mechanisms remain unknown yet. In this study, two undescribed eremophilane sesquiterpenoids fischerins A (1) and B (2), together with 8 known sesquiterpenoid derivatives (3-10), were isolated from the whole plant of L. fischeri. Their structures were identified by detailed spectroscopic and ECD analyses. 3-Oxo-8-hydroxyeremophila-1,7(11)-dien-12,8-olide (6) showed the most inhibitory effect on NO production in LPS-stimulated RAW 264.7 cells with the IC50 value of 6.528 μM. Meanwhile, compound 6 also decreased the mRNA expression of pro-inflammatory factors IFN-γ, IL-1β, IL-6 and TNF-α via downregulating NF-κB signaling pathway in vitro. Furthermore, compound 6 reduced the mortality, murine sepsis score, the serum TNF-α level and organic damage in a mouse model of sepsis. These findings indicated that compound 6 possessed the potent anti-inflammatory activity and had the potential as a promising drug candidate for sepsis therapy.
Oral anticoagulants are effective in the treatment and prevention of venous and arterial thrombotic events. For more than 50 years the only class of anticoagulant available had been the vitamin K antagonist (VKA), warfarin, which requires frequent blood work for monitoring. Apixaban is a new approved anticoagulant that is used to treat patients who have blood clots or are at risk for developing blood clots. Unlike warfarin, the use of apixaban does not require frequent blood work for monitoring and is associated with lower bleeding risk. All anticoagulation therapies are associated with spontaneous or provoked bleeding risk and reversal of their blood thinning effects might be needed. Reversal of anticoagulation may also be needed in cases where emergent or urgent surgery is indicated. There is currently no available reversal agent for apixaban. Prothrombin complex concentrate (PCC) contain clotting factors and can replace factors inhibited by anticoagulants. In a recent study in the Netherlands a four factor prothrombin complex concentrate, Cofact (not available in the USA) was shown to be able to reverse the anticoagulation effects of another factor Xa inhibitor, rivaroxaban. Kcentra is a four factor prothrombin complex concentrate that was FDA approved in 2013 and is used as an antidote to treat people with bleeding associated with taking warfarin. It contains clotting factors II, VII, IX and X derived from donated blood and could be effective in reversing the anticoagulation effects of the factor Xa inhibitor, apixaban. No effective reversal agent for apixaban exists. Physicians struggle with bleeding in patients who are on apixaban. Indeed, this is not an uncommon problem for patients who suffer brain bleeds or trauma. This study could potentially identify Kcentra as reversal agent for patients taking apixaban. This study will test the hypothesis that Kcentra has the potential to significantly reduce the anticoagulation effect of apixaban as measured by thrombin generation assay at 30 minutes post infusion of Kcentra as compared to placebo infusion in subjects dosed to steady state with apixaban.
The invention relates to a physiological saline solution containing 0.5% phenol for the diagnostic test of cancer, which comprises nucleohistone of (a) chorionic villi of placenta of human beings or animals or (b) cancer tissue.  The chorionic villi or cancer tissue is extracted with water or an aqueous solution of sodium chloride and nucleoprotein precipitated by adjusting the pH of the extract to 4.5 by the addition of acid, or calcium chloride to 0.01 mole. concentration or sodium chloride to 0.14 mole. concentration, the precipitate is dissolved in aqueous solution and nucleohistone separated by known methods for separating nucleic acid from aqueous solution.  Thus the precipitate may be dissolved in aqueous sodium chloride and dialysed against aqueous sodium chloride to remove protamine.  The solution in the dialysis bag is heated to 80 DEG  C. for 1 minute, filtered and ethanol added to precipitate nucleohistone which is dried and then dissolved in physiological saline solution containing 0.5% phenol.
The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
FIELD: medicine, endocrinology, phytotherapy. SUBSTANCE: invention relates to agents of plant origin for recovery of thyroid function. Species has rice, celandine, plantain and thuja taken at the definite ratio. Species can be used in different medicinal forms: decoction, tablets, capsules. EFFECT: enhanced therapeutic effect of an agent. 4 cl, 5 ex
PROBLEM TO BE SOLVED: To obtain a W/O-type emulsified cosmetic giving excellent feeling to the skin, having high stability with time and exhibiting extremely low viscosity even at a high oil content by using a specific emulsifying agent. SOLUTION: A polyglycerol monofatty acid ester derived from a fatty acid and a glycidol and having high monoester content is used as an emulsifying agent in combination with glycerol, an oil base and water. The sum of the polyglycerol monofatty acid ester, glycerol and the oil base is preferably 50-70wt.%. The fatty acid to be used as a raw material is e.g. caproic acid, caprylic acid or lauric acid and the oil base is e.g. liquid paraffin, vaseline or isopropyl myristate. The amount of the oil base is about 50-75wt.% based on the sum of the polyglycerol monofatty acid ester and glycerol, the amount of glycerol is about 10-20wt.% based on the total composition and the amount of water is preferably about 25-50wt.%. The cosmetic is useful e.g. as an antisuntan milky lotion.
The invention provides a target lncRNA for learning and memory dysfunction caused by microwave radiation: mstrg.27033.1, the target comprising at least one of the following sequences: 1, SEQ ID NO; or an RNA sequence with at least 70% identity to the RNA sequence shown in SEQ ID NO. 1, or an RNA sequence with at least 80% identity to the RNA sequence shown in SEQ ID NO. 1, or an RNA sequence with at least 85% identity to the RNA sequence shown in SEQ ID NO. 1, or an RNA sequence with at least 90% identity to the RNA sequence shown in SEQ ID NO. 1, or an RNA sequence with at least 95% identity to the RNA sequence shown in SEQ ID NO. 1, or an RNA sequence with at least 99% identity to the RNA sequence shown in SEQ ID NO. 1.
Studies indicate that the lysine-specific demethylase 4A (KDM4A), acts as a key player in neuropathic pain, driving the process through its involvement in promoting neuroinflammation. Emerging evidence reveals that C-C Motif Chemokine Ligand 2 (CCL2) participates in neuroinflammation, which plays an important role in the development and maintenance of neuropathic pain. However, it remains unclear if KDM4A plays a role in regulating CCL2 in neuropathic pain. This study found that following spinal nerve transection (SNT) of the lumbar 5 nerve root in rats, the expression of KDM4A and CCL2 increased in the ipsilateral L4/5 dorsal root ganglia (DRG). Injecting KDM4A siRNA into the DRGs of rats post-SNT resulted in a higher paw withdrawal threshold (PWT) and paw-withdrawal latency (PWL) compared to the KDM4A scRNA group. In addition, prior microinjection of AAV-EGFP-KDM4A shRNA also alleviates the decrease in PWT and PWL caused by SNT. Correspondingly, microinjection of AAV-EGFP-KDM4A shRNA subsequent to SNT reduced the established mechanical and thermal hyperalgesia. Furthermore, AAV-EGFP-KDM4A shRNA injection decreased the expression of CCL2 in DRGs. ChIP-PCR analysis revealed that increased binding of p-STAT1 with the CCL2 promoter induced by SNT was inhibited by AAV-EGFP-KDM4A shRNA treatment. These findings suggest that KDM4A potentially influences neuropathic pain by regulating CCL2 expression in DRGs.